Supervisor Database Search

Guidance for ICAT Supervisors

The ICAT Supervisor list is reviewed annually by the partner universities and updated online in March/April each year.

You can read about the ICAT supervisor selection process and eligibility criteria below:

Terms of reference/guide to supervising ICAT Fellows.

You can read the terms of reference for supervisors actively supervising ICAT Fellows below:

Supervisor Database

Search for supervisors below. You can filter your search using the options and select multiple fields by holding CTRL (Cmd on Mac) + clicking multiple options in a list.

← Go back

Full NameProfessor Seamas Donnelly

Clinical Medicine

Trinity College Dublin

Webpage:wordpress.com

Email hidden; Javascript is required.

Research Fields
  • genetics, genomics and molecular biology
Postgrad Medical Specialties
  • Medicine
Medical Subspecialties
  • Infectious diseases
  • Immunology
  • Respiratory Medicine
  • Rheumatology
My Work

Professor Seamas Donnelly's research activities represent a classical bench to bedside approach. The Donnelly group is part of the School of Medicine at Trinity College Dublin and is based in the state of the art Trinity Biomedical Sciences Institute on Pearse Street in the heart of Dublin. We are a multidisciplinary research group working in the area of translational medicine with a focus on respiratory disease.

Our research is based on identifying significant clinical problems and then starting with a hypothesis working at the bench take our findings through to the clinic with the potential of designing new therapies or cahnging the way we practioce medicine. Particular questions that we are currently working on include:

How does cancer evade our own defenses?
What is the genetic basis for patients developing idiopathic pulmonary fibrosis?
Can we develop novel nanoparticle aerosolised delivery systems for new therapies?
Can we overcome antibiotic resistance?
Why do patients after bone marrow transplantation get progressive lung problems with associated significant mortality?
Why do rheumatoid arthritis patients develop pulmonary fibrosis?

Selected Department Publications

- O'Reilly C, et al. Targeting MIF in Cancer: Therapeutic Strategies, Current Developments, and Future Opportunities. Med Res Rev. 2016 May;36:440-60.

- Mawhinney L, et al . Macrophage migration inhibitory factor (MIF) enzymatic activity and lung cancer. Mol Med. 2015 Apr 16;20:729-35.

- O'Dwyer DN, et al. Targeting defective Toll-like receptor-3 function and idiopathic pulmonary fibrosis. Expert Opin Ther Targets. 2015;19(4): 507-514.

- Hams E, et al. IL-25 and type 2 innate lymphoid cells induce pulmonary fibrosis. Proc Natl Acad Sci U S A. 2014;111(1):367-72.

- O'Dwyer DN, et al. Rheumatoid Arthritis (RA) associated interstitial lung disease (ILD). Eur J Intern Med. 2013 Oct;24(7):597-603.

Scroll to Top